InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (12 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
12
T+90 hit rate
100%
T+90 mean return
+0.6%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Robb Gary Charles, Directeur Commercial. Insider active across 2 companies, notably Corcept Therapeutics INC. Aggregated, 51 filings have been recorded. Breakdown: 0 buy · 12 sells. Total volume traded: €3.8m. Activity tracked since 30 August 2021. The latest transaction was disclosed on 2 June 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Declarations51 total
776 shares@ US$70.440.0008% mcap0.9% of flowCommon StockSEC:0001193125-26-256002:0
776 shares0Common StockSEC:0001193125-26-256002:1
358 shares@ US$70.440.0004% mcap0.4% of flowCommon StockSEC:0001193125-26-256002:2
1,000 shares0Common StockSEC:0001193125-26-227411:1
1,000 shares0Common StockSEC:0001193125-26-227411:2
5,300 shares0Common StockSEC:0001193125-26-227411:0
5,300 shares0Common StockSEC:0001193125-26-227411
2,279 shares@ US$75.853.0% of flowCommon StockSEC:0000950170-25-076417:0
313 shares0Common StockSEC:0000950170-25-057620:0
233 shares0Common StockSEC:0000950170-25-044069:0
4,625 shares0Common StockSEC:0000950170-25-039604:0
250 shares@ US$60.580.3% of flowCommon StockSEC:0000950170-25-032708:0
11,000 shares@ US$3.290.7% of flowCommon StockSEC:0000950170-25-002439:0
324 shares@ US$57.680.4% of flowCommon StockSEC:0000950170-24-133440:0
2,609 shares@ US$56.202.8% of flowCommon StockSEC:0000950170-24-131176:0
415 shares0Common StockSEC:0000950170-24-111052:0
300 shares0Common StockSEC:0000950170-24-108226:0
254 shares@ US$35.300.2% of flowCommon StockSEC:0000950170-24-104192:0
3,101 shares@ US$35.712.0% of flowCommon StockSEC:0000950170-24-101501:0
11,000 shares@ US$3.290.7% of flowCommon StockSEC:0000950170-24-081594:0
2,650 shares0Common StockSEC:0000950170-24-076962:0
14,000 shares@ US$3.290.8% of flowCommon StockSEC:0000950170-24-070045:0
724 shares@ US$30.170.4% of flowCommon StockSEC:0000950170-24-069612:0
11,000 shares@ US$3.290.7% of flowCommon StockSEC:0000950170-24-066889:0
656 shares@ US$24.060.3% of flowCommon StockSEC:0000950170-24-026707:0
25 of 51 declarations
About Robb Gary Charles
Gary Charles Robb is the Chief Business Officer at CORCEPT THERAPEUTICS INC. He is responsible for the company's business strategy, aiming to expand its operations and increase market share. With strong experience in business development, he plays a key role in identifying new opportunities and optimizing Corcept's operations.
